What is Accent Therapeutics?
Accent Therapeutics is dedicated to pioneering small molecule therapeutics by leveraging its deep expertise in RNA-modifying protein biology. The company targets critical intracellular dependencies across a spectrum of cancer types, aiming to address significant unmet medical needs for large patient populations. With a robust pipeline featuring first-in-class and best-in-class programs, Accent Therapeutics is positioned to drive the development of life-changing treatments for individuals battling cancer. Their collaborative approach and commitment to scientific rigor are central to their mission of advancing oncology therapeutics.
How much funding has Accent Therapeutics raised?
Accent Therapeutics has raised a total of $178M across 3 funding rounds:
Series A
$40M
Series B
$63M
Series C
$75M
Series A (2018): $40M, investors not publicly disclosed
Series B (2020): $63M led by Droia Ventures, Atlas Venture, The Mark Foundation for Cancer Research, The Column Group, NS Investment, Google Ventures, AbbVie Biotech Ventures , Inc., and EcoR1 Capital LLC
Series C (2024): $75M supported by Bristol-Myers Squibb, Johnson & Johnson Innovation, Mirae Asset Financial Group, and The Column Group
Key Investors in Accent Therapeutics
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical organization focused on discovering, developing, and manufacturing prescription medications for serious patient needs across oncology, cardiovascular disease, immunoscience, and virology. They actively engage in research partnerships to accelerate the development of new treatment options.
Johnson & Johnson Innovation
Johnson & Johnson Innovation partners with entrepreneurs and early-stage businesses to develop healthcare solutions, operating through regional innovation centers to access global science and technology. They aim to create a leading innovation network for transformational healthcare solutions.
The Column Group
The Column Group is a venture ecosystem dedicated to advancing life sciences innovation, supporting the formation and growth of biotechnology companies through an edge-to-edge investment model that nurtures early-stage technology platforms and later-stage programs.
What's next for Accent Therapeutics?
The recent major strategic investment in Accent Therapeutics signals a pivotal stage for the company, likely enabling accelerated development of its promising pipeline and expansion of its research and development capabilities. This capital infusion is expected to fuel clinical trials, enhance manufacturing processes, and potentially forge new strategic partnerships. Accent Therapeutics' focus on addressing critical intracellular dependencies in cancer positions it for significant growth and impact in the biopharmaceutical landscape, with the company poised to advance its therapeutic candidates toward market approval and patient accessibility.
See full Accent Therapeutics company page
